How Should Clinicians Address the Link Between Atopic Dermatitis and Allergy?

Jay A. Lieberman, MD, professor at the University of Tennessee Health Science Center, noted the value of viewing atopic dermatitis within the broader context of allergic disease during his presentation, ‘Connecting AD to Other Dermatologic Disorders and Related Comorbidities,’ at the 2026 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville.¹

In his interview with the HCPLive team, Lieberman emphasized that while dermatologists and allergists share the same goal of improving patient outcomes and quality of life, those working in allergy often look at atopic dermatitis through a wider lens. Instead of aiming only toward the skin manifestations of disease, Lieberman noted many of those with atopic dermatitis also report other atopic conditions, including asthma, allergic rhinitis, and food allergies.

As a result, treatment decisions are often guided by a patient's broader allergic disease profile and the opportunity to address multiple conditions simultaneously. A major theme of Lieberman’s discussion centered on the growing evidence supporting early intervention in atopic disease. He pointed to ongoing research evaluating whether aggressive management of eczema early in life, including the use of emollients and low-dose topical corticosteroids, may help restore skin barrier function and alter the trajectory of disease development.

Investigators are increasingly examining whether such strategies could reduce not only the long-term burden of atopic dermatitis but also the risk of developing additional allergic conditions. Lieberman also pointed to advances in food allergy prevention as another example of how early intervention is reshaping clinical practice. The growing amount of literature supporting early introduction of allergenic foods has demonstrated that proactive management can reduce food allergy risk, he noted, reinforcing the broader concept that early action may influence the progression of atopic disease.

The discussion additionally highlighted the rapidly evolving therapeutic landscape in atopic dermatitis. With an expanding number of biologics and systemic therapies now available, clinicians are faced with more opportunities to personalize treatment than ever before. Lieberman noted that evaluating a patient’s comorbid conditions has become increasingly important when selecting therapy, as certain treatments may provide benefits across multiple atopic diseases.

Overall, Lieberman underscored the need for a comprehensive, patient-centered approach to disease management. As understanding of the connections between eczema, food allergy, asthma, and other allergic conditions continues to grow, clinicians may be better positioned to intervene earlier and to tailor their treatment strategies more effectively.

Disclosures: Lieberman has previously been associated with Novartis Pharmaceuticals, ABBVIE, Genentech, Aquestive Therapeutics.

References

1. Lieberman J, Hawkes J. Connecting AD to Other Dermatologic Disorders and Related Comorbidities. Session presented at: 2026 Revolutionizing Atopic Dermatitis Conference; June 17-19, 2026; Nashville, TN.